

## References

S-141

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. Curley SA, Stuart KE, Schwartz JM, Carithers RL. Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injections, thermal ablation, and cryoablation. UpToDate. Last updated October 16, 2015.
3. Ang Chan J, Kulke M, Clancy TE. Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretions. UpToDate, Last Reviewed Jan 07, 2015.
4. Canadian Cancer Society. Liver Cancer. 2016.
5. NIH National Cancer Institute. Cryosurgery in Cancer Treatment: Questions and Answers. 2016.
6. Littrup P, Aoun H, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors long-term experience of a large U.S. series. *Abdom Radiol.* 2016;41(4) 757-780.
7. Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. 2015;61 (5): 1579-1590.
8. American Cancer Society. Tumor Ablation for Liver Cancer. April 28, 2016.
9. European Society for Medical Oncology. Microwave Ablation for Treating Liver Metastases. May 2016.
10. FDA/CEDR resources page. Food and Drug Administration Web site. <http://www.fda.gov/cder/approval/index.htm>. Accessed April 7, 2017.
11. Song K. Percutaneous cryoablation for hepatocellular carcinoma. *Clin Mol Hepatol.* 2016; 22:509-515.

12. Kang T, Rhim H, Song K, et al. Radiofrequency ablation of hepatocellular carcinoma with a “Nodule-in-Nodule” appearance: Long-term follow-up and clinical implications. *Cardiovasc Interv Radiol.* 2017; 40:401-409.
13. Changyong E, Wang D, Yu Y, et al. Efficacy comparison of radiofrequency ablation and hepatic resection for hepatocellular carcinoma: A meta-analysis. *J Cancer Res Ther.* 2017; 13: 625-630.
14. National Comprehensive Cancer Network. Hepatocellular Carcinoma. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/PDF/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf).
15. National Comprehensive Cancer Network. Colon Cancer. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf).
16. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). 2019.
17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf).
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf).
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/colon.pdf](https://www.nccn.org/professionals/physician_gls/PDF/colon.pdf).
20. Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. *World J Gastrointest Pharmacol Ther* 2016; 7(4):477.
21. Wang WD, Xu LF, Zhang L, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma with the Milan criteria: A meta-analysis. *Korean J Radiol.* 2018; 19(4): 613-622.
22. Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma—A multidisciplinary approach. *Int J Mol Sci.* 2019; 20(6):1465.

23. Zhao WJ, Zhu GQ, Wu YM, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: results of propensity score-weighted analysis. *Onco Targets Ther.* 2019; 12:10389.
24. Rong G, Bai W, Dong Z, et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. *PLoS One.* 2015; 10(4):e0123065.
25. Kutlu OC, Chan JA, Aloia TA, et al. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. *Cancer.* 2017; 123(10):1817-27.